DDInter534 DDInter281
A benzodiazepine with anticonvulsant, anxiolytic, sedative, muscle relaxant, and amnesic properties and a long duration of action. Its actions are mediated by enhancement of gamma-aminobutyric acid activity. It is used in the treatment of severe anxiety disorders, as a hypnotic in the short-term management of insomnia, as a sedative and premedicant, as an anticonvulsant, and in the management of alcohol withdrawal syndrome. (From Martindale, The Extra Pharmacopoeia, 30th ed, p589) Given diazepam's storied history as a commonly used and effective medication for a variety of indications, contemporary advancements in the formulation and administration of the agent include the development and US FDA approval of an auto-injectable formulation for the rapid treatment of uncontrolled seizures in 2015-2016. Combining diazepam, a proven effective therapy for acute repetitive seizures
Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. Both heavy chains of canakinumab contain oligosaccharide chains linked to the protein backbone at asparagine 298 (Asn 298). Canakinumab binds to human IL-1β and neutralizes its inflammatory activity by blocking its interaction with IL-1 receptors, but it does not bind IL-1alpha or IL-1 receptor antagonist (IL-1ra). Canakinumab is marketed under the brand name Ilaris and indicated for patients 4 years of age and older to treat Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS), which are both part of the Cryopyrin-Associated Periodic Syndromes (CAPS) as well as for patients 2 years of age and older to treat systemic juvenile idiopathic arthritis (SJIA). Clinical trials have established the administration of canakinumab every 2 weeks to be safe and effective, offering a considerable advantage over the existing treatment with the human IL-1 receptor antagonist, anakinra, which must be injected daily and which is often poorly tolerated by patients.
Diazepam {u} (Compound) resembles {v} (Compound) Alprazolam
Alprazolam {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Canakinumab
Diazepam {u} (Compound) resembles {v} (Compound) Clobazam
Clobazam {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Canakinumab
Diazepam {u} (Compound) resembles {v} (Compound) Alprazolam
Alprazolam {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brigatinib
Brigatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Canakinumab
Diazepam {u} (Compound) resembles {v} (Compound) Clonazepam
Clonazepam {u} (Compound) resembles {v} (Compound) Alprazolam
Alprazolam {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Canakinumab
Diazepam {u} (Compound) resembles {v} (Compound) Midazolam
Midazolam {u} (Compound) resembles {v} (Compound) Alprazolam
Alprazolam {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Canakinumab
Diazepam {u} (Compound) resembles {v} (Compound) Clobazam
Clobazam {u} (Compound) resembles {v} (Compound) Alprazolam
Alprazolam {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Canakinumab
Diazepam {u} (Compound) resembles {v} (Compound) Alprazolam
Alprazolam {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dasatinib
Dasatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Canakinumab
Diazepam {u} (Compound) resembles {v} (Compound) Clobazam
Clobazam {u} may cause a minor interaction that can limit clinical effects when taken with {v} Theophylline
Theophylline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Canakinumab
Diazepam {u} (Compound) resembles {v} (Compound) Alprazolam
Alprazolam {u} may cause a minor interaction that can limit clinical effects when taken with {v} Theophylline
Theophylline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Canakinumab
Diazepam {u} (Compound) resembles {v} (Compound) Alprazolam
Alprazolam {u} may cause a minor interaction that can limit clinical effects when taken with {v} Prednisolone
Prednisolone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Canakinumab
Diazepam (Compound) resembles Alprazolam (Compound) and Alprazolam may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab
Diazepam (Compound) resembles Clobazam (Compound) and Clobazam may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab
Diazepam (Compound) resembles Alprazolam (Compound) and Alprazolam may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab
Diazepam (Compound) resembles Clonazepam (Compound) and Clonazepam (Compound) resembles Alprazolam (Compound) and Alprazolam may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab
Diazepam (Compound) resembles Midazolam (Compound) and Midazolam (Compound) resembles Alprazolam (Compound) and Alprazolam may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab
Diazepam (Compound) resembles Clobazam (Compound) and Clobazam (Compound) resembles Alprazolam (Compound) and Alprazolam may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab
Diazepam (Compound) resembles Alprazolam (Compound) and Alprazolam may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab
Diazepam (Compound) resembles Clobazam (Compound) and Clobazam may cause a minor interaction that can limit clinical effects when taken with Theophylline and Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab
Diazepam (Compound) resembles Alprazolam (Compound) and Alprazolam may cause a minor interaction that can limit clinical effects when taken with Theophylline and Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab
Diazepam (Compound) resembles Alprazolam (Compound) and Alprazolam may cause a minor interaction that can limit clinical effects when taken with Prednisolone and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab